All News

Poster presentations at SOHO 2026 may inform practice across acute lymphoblastic leukemia, acute myeloid leukemia, and chronic lymphocytic leukemia.

Camizestrant/palbociclib did not significantly improve PFS vs anastrozole/palbociclib in first-line ER+/HER2– breast cancer in the phase 3 SERENA-4 trial.

The FDA has set a new action date of March 3, 2027, for zanzalintinib/atezolizumab for previously treated metastatic colorectal cancer.

The FDA approved the first and only photodynamic therapy for the treatment of a skin cancer.

The FDA has approved a FET-PET imaging agent, to help characterize recurrent or progressive glioma from treatment-related changes.

Bladder-sparing options for BCG-unresponsive non-muscle invasive bladder cancer have transformed since 2020, according to Saum Ghodoussipour, MD.

Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.

Final phase 3 MATTERHORN data position perioperative durvalumab plus FLOT as a new standard in resectable gastric or gastroesophageal junction adenocarcinoma.

The risk of infections with epcoritamab plus R2 appeared to be level off after the first 4 cycles of therapy in the EPCORE FL-1 trial.

At SOHO 2026, David Sallman, MD, explained why ofirnoflast produced responses across MDS subtypes, including in a patient with TP53-mutant disease.

Josef Vymazal, MD, discussed how gadopiclenol’s pharmacokinetics may explain why delayed double-dose imaging outperformed delayed single-dose imaging for detecting brain metastases.

Immunochemotherapy, bispecifics, and next-generation BTK inhibitors dominated discussion of ENKTL, MZL, and Waldenström macroglobulinemia at a SOHO session.

Erica L. Mayer, MD, MPH, discussed the practical questions clinicians must answer as the SERENA-6 early-switch approach with camizestrant enters practice.

DISC-3405 may serve as an adjunctive therapy, not a replacement, for hydroxyurea or interferon, according to Naseema Gangat, MBBS.

DISC-0974 may have utility as monotherapy or in combination with other JAK inhibitors, according to Naseema Gangat, MBBS.

Erica L. Mayer, MD, MPH, explained why oncologists should switch to camizestrant at ESR1 mutation emergence rather than reserve oral SERDs for progression.

Josef Vymazal, MD, discussed a randomized study showing delayed double-dose gadopiclenol significantly improved detection of small brain metastases compared with standard imaging.

Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.

At SOHO 2026, Jasmine Zain, MD, discussed communicating the FDA’s boxed warning for secondary malignancies post–CAR T-cell therapy to patients.

Initial phase 2 SURF302 data show a 79% ORR with 60 mg once-daily oral dabogratinib in FGFR3-altered low-grade intermediate-risk NMIBC.

Combination approvals for revumenib and ziftomenib in relapsed/refractory acute myeloid leukemia may arrive before frontline approvals, according to Eunice Wang, MD.

ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.

Adding atezolizumab to neoadjuvant chemotherapy did not significantly improve EFS in early TNBC, but node-positive and high-TIL subgroups showed benefit.

Data at SOHO 2026 show how FLT3 inhibitors and venetoclax-based triplets have reshaped induction, consolidation, and maintenance therapy in FLT3-mutated AML.

Josef Vymazal, MD, explained why high-relaxivity contrast agents are critical for detecting small brain metastases, despite weaker agents remaining suitable for other indications.

Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.

The first patient has been dosed in a phase 2 trial evaluating paxalisib plus gemcitabine in children and young adults with recurrent atypical teratoid/rhabdoid tumor.

The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.

The FDA has granted accelerated approval to sevabertinib for metastatic non-squamous NSCLC with HER2 TKD activating mutations based on results from the SOHO-01 trial.

Data from the phase 3 DeLLphi-305 trial also showed meaningful improvements in progression-free survival and responses with durvalumab/tarlatamab in SCLC.